Eglaro-S Tablets Specification

Requires Prescription (YES/NO)

Yes

Generics

Ertugliflozin + Sitagliptin

Used For

Diabetes

How it works

Ertugliflozin : Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Ertugliflozin also causes an osmotic diuresis, which may result in increase of urinary glucose excretion. Sitagliptin : Sitagliptin improve glycemic control in patients with type 2 diabetes by enhancing the levels of active incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), In addition, GLP-1 lowers glucagon secretion from pancreatic alpha cells. Decreased glucagon concentrations, along with higher insulin levels, lead to reduced hepatic glucose production, resulting in a decrease in blood glucose levels.

Eglaro-S Tablets Usage And Safety

Dosage

Ertugliflozin + Sitagliptin

Side Effects

Pancreatitis, hypotension, ketoacidosis, acute kidney injury, impairment in renal function, urosepsis, pyelonephritis, lower limb amputation, heart failure, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (fournier’s gangrene), genital mycotic infections, hypersensitivity reactions, increases in low-density lipoprotein, severe and disabling arthralgia, bullous pemphigoid, upper respiratory tract infection, nasopharyngitis, urinary tract infections, vaginal pruritus, increased urination, back pain, weight decreased and headache.

Drug Interactions

It may increase the risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue.Patients receiving digoxin should be monitored appropriately .

Indication

It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Ertugliflozin and Sitagliptin is appropriate.

When not to Use

Known hypersensitivity to Ertugliflozin, Sitagliptin and to any of the excipient of the product. - Severe renal impairment, end-stage renal disease (ESRD) or on dialysis.

Eglaro-S Tablets Precautions

Precaution

Patients should be observed carefully for signs and symptoms of pancreatitis.

Eglaro-S Tablets Warnings

Warning 1

Ertugliflozin causes intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating Ertugliflozin + Sitagliptin .

Warning 2

Treatment with medicines containing SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated.

Warning 3

Ertugliflozin + Sitagliptin who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of presenting blood glucose levels, as ketoacidosis associated with Ertugliflozin + Sitagliptin may be present even if blood glucose levels are less than 250mg/dL. If ketoacidosis is suspected, Ertugliflozin + Sitagliptin should be discontinued.

Eglaro-S Tablets Additional Information

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.